This tiny MRNA biotech announces huge partnership

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 September 26, 2024 Good morning, 360! Along with our biggest movers, here’s a special invitation to join Jeff Bishop and technical analyst wizard - JC Parets - today at 1pm EST in [Market Masters]( — learn a thing… or ten! Be the best prepared trader on the Street! FOCUS LIST🔎 TBIO - Up over 120% in the pre-market after announcing collaboration with Beckman Coulter Life Sciences to revolutionize DNA and mRNA Synthesis KTTA - Up over 50% in pre after announcing positive initial safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in Advanced Cancer TRNR - Up over 16% in pre after announcing it has secured exclusive distribution for CLMBR with PrimaFit in fast-growing Indonesia and already receives second order in third quarter Jeff Bishop Hosts Technical Wizard JC Parets! 💥LIVE Thursday @ 1pm EST💥 JC’s work has been featured regularly on Bloomberg, CNBC, Fox Business, ABC, CNN, Wall Street Journal and many other financial media outlets around the world - now is your chance to chat with him! [TAKE YOUR SEAT TODAY 1ET]( HOTLIST🔥 TBIO - Up over 120% in the pre-market after announcing collaboration with Beckman Coulter Life Sciences to revolutionize DNA and mRNA Synthesis Telesis Bio, Inc. (TBIO) is a synthetic biology company that manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. In the after-hours yesterday, the [company announced]( a new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation that will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio’s Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The stock traded up over 120% in the pre-market in reaction to the partnership. The $4.70 area acted as support in the after-hours and the pre-market and will be an important level to watch. Above it, targets to the upside are $5, $5.20, $5.50 and then the after-hours high at $5.79. Beyond that, $6, $6.50, $7 and $8.50 come into play. Below $4.70, targets to the downside are $3.50, $3 and then a gap fill at $2.32. 🚂 CHOO CHOO 🚂 Don’t be like DayTradingForBailMoney… [Hop aboard the Bullseye Unlimited train TODAY!]( (Or call Davis to Upgrade 1-800-585-4488) KTTA - Up over 50% in pre after announcing positive initial safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in Advanced Cancer Pasithea Therapeutics Corp. (KTTA) is a biotechnology company that engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. In the pre-market this morning, the [company announced]( safety, tolerability, pharmacokinetic (PK) and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its Phase 1 clinical trial of PAS-004, being conducted at four clinical sites in the United States. Highlights include: - Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle - No treatment-related adverse events (TRAEs) or dose-limiting toxicities (DLTs) observed to date, including no rash or gastrointestinal (GI) AEs - Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities - Half-life of approximately 70 hours supports once-daily or less frequent oral dosing - Distinctive MEK inhibitor profile for the treatment of both NF1-related plexiform and cutaneous neurofibromas, cancer, and other opportunities The stock traded up over 60% in the pre-market in reaction to the positive news. The first target for bulls is the pre-market high at $6.57. Beyond that, $7, $8 and $9.25 come into play. Below $6.57, targets to the downside are $6, $5.50, $5, $4.70 and then a gap fill at $3.85. TRNR - Up over 16% in pre after announcing it has secured exclusive distribution for CLMBR with PrimaFit in fast-growing Indonesia and already receives second order in third quarter Interactive Strength Inc. (TRNR) doing business as FORME, operates digital fitness platform that provides connected fitness hardware products and related accessories in the United States. In the pre-market this morning, the [company announced]( it has secured exclusive distribution and received two orders in the third quarter for CLMBR in the fast-growing Indonesia with PrimaFit, the leading distributor of best-in-class brands in the country. PrimaFit, based in Jakarta, is the leading distributor of best-in-class brands in Indonesia and will represent CLMBR exclusively Indonesia is the largest economy in the region and is a G20 country with high GDP growth PrimaFit received its initial order in July and placed a larger second order in September that combined is almost six-figures TRNR stock traded up over 16% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $0.27. Beyond that, targets to the upside are $0.33, $0.45 and $0.60 come into play. Below $0.27, targets to the downside are $0.25, $0.23 and then a gap fill at $0.2189. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](